Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Revenue (2021)

Cullinan Therapeutics has reported Revenue over the past 1 years, most recently at $18.9 million for Q1 2021.

  • Quarterly results put Revenue at $18.9 million for Q1 2021, changed N/A from a year ago — trailing twelve months through Dec 2021 was $18.9 million (changed N/A YoY), and the annual figure for FY2021 was $18.9 million, changed.
  • Revenue for Q1 2021 was $18.9 million at Cullinan Therapeutics.
  • Over the last five years, Revenue for CGEM hit a ceiling of $18.9 million in Q1 2021 and a floor of $18.9 million in Q1 2021.